Zalifrelimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Zalifrelimab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 5 August 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: HOLD / OPTION
Decision memo
Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.
The central underwriting question is whether Zalifrelimab can convert its Not disclosed profile and Not disclosed biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Zalifrelimab (query alias: Zalifrelimab) |
|---|---|
| Modality / target | Not disclosed; Not disclosed; Not disclosed |
| Highest global status | Not disclosed |
| Originator | Not disclosed |
| Active developers | Not disclosed |
The MCP disease footprint includes no disclosed indication. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT05033132 | Phase 2 | Withdrawn | Not disclosed | Objective Response Rate (ORR) Of Balstilimab Monotherapy Per Independent Review Committee (IRC) Assessment Based Upon Response Evaluation Criteria In Solid Tumours (RECIST) 1.1 |
| NCT06782555 | Phase 1/2 | Recruiting | 71 | Incidence and severity of adverse events including dose-limiting toxicities |
| NCT05375903 | Phase 1 | Completed | 51 | Incidence of dose-limiting toxicities (DLTs) and treatment-emergent adverse events (TEAEs) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Treatment of recurrent non-muscle invasive bladder cancer with UGN-301 (zalifrelimab) alone and in combination: A phase 1 dose escalation study.
Phase 1; n=41; evaluation: Positive. Reported fields: CR(12-week; CIS ± Ta/T1 patients) = 100.0 % ; CR(12-week; CIS ± Ta/T1 patients) = 33.3 % ; CR(12-week; CIS ± Ta/T1 patients) = 33.3 %
UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer
Phase 1; n=not disclosed; evaluation: Positive. Reported fields: RFS(12-week) = 46% (6 of 13) of those with Ta/T1 disease
A Phase 1/2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884) in Subjects With Advanced or Refractory Cancer and in Subjects Who Have Progressed During Treatment With a PD-1/PD-L1 Inhibitor as Their Most Recent Therapy
Phase 1/2; n=89; evaluation: not stated. Reported fields: -; -; Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs) of Zalifrelimab = 0 Participants
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Zalifrelimab addresses its disclosed development indications. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Not disclosed—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 5 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-11-06 | UroGen hands anti-CTLA-4 drug back to Agenus after being unimpressed with phase 1 data | Phase 2 | US$10.0M upfront; US$200.0M milestones |
| 2024-05-06 | Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement | Phase 2 | US$75.0M upfront |
| 2021-01-26 | Agenus Enters into Clinical Collaboration with Nelum for Zalifrelimab Combination | Phase 2 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
HOLD / OPTION
Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 5 August 2026. Counts and status fields may change as source records update.
